Effect of 6-8 weeks of oral ursodeoxycholic acid administration on serum concentrations of fasting and postprandial bile acids and biochemical analytes in healthy dogs.

Background: Ursodeoxycholic acid (UDCA) is commonly used for the treatment of hepatobiliary disease. UDCA is a bile acid that can be detected in the bile acid assay. Its effect on biochemical analytes is unknown. Objectives: The aim of this study was to determine the effect of 6-8 weeks of UDCA administration on fasting and postprandial concentrations of serum bile acids (SBA), cholesterol, triglycerides, bilirubin, and liver enzyme activities in healthy dogs. Methods: Twenty healthy dogs received UDCA for 6-8 weeks. CBC, biochemistry profile, urinalysis, fasting and postprandial SBA, and hepatobiliary ultrasound examination were performed prior to starting UDCA (timepoint 0) and after 6-8 weeks of therapy, while animals were still receiving UDCA (timepoint 1). Timepoint 0 and timepoint 1 values were compared with a paired t-test. SBA were remeasured 72 hours after UDCA discontinuation. Results: Only mean fasting SBA at timepoint 1 increased significantly (P = .03) from timepoint 0 (2.26 mu mol/L at time 0 and 3.81 mu mol/L at time 1) but were not elevated above the normal reference interval (0-9 mu mol/L). Two dogs had timepoint 1 fasting SBA above the reference interval (10 and 11.7 mu mol/L). One dog had timepoint 1 postprandial SBA above the reference interval at 20.1 mu mol/L (reference interval 0-17 mu mol/L). Repeat SBA 72 hours after UDCA discontinuation were normal. Conclusions: Long-term administration of UDCA to healthy dogs may increase fasting SBA above pretreatment values (typically within the reference interval). Long-term administration of UDCA to healthy dogs does not alter liver enzyme activities, and bilirubin, cholesterol, or triglyceride concentrations.